ERBB2 and breast cancer: The combination of lapatinib and entinostat has exhibited synergy in two in vivo models of HER2+ breast cancer (BT474 and SUM190), and entinostat-resensitized trastuzumab/lapatinib-resistant cell lines to lapatinib through induction of BIM1 [124].